The Pharmaceutical industry has been growing rapidly in recent years due to several factors such as increasing demand for generic drugs, growing healthcare infrastructure, and favourable government policies. The Indian pharmaceutical market continues to clock a growth of 9 to 10 percent.
Ace investors in India are known for their expertise in identifying high-growth opportunities and managing risk in the stock market. These investors have built their wealth and reputation by consistently making bold decisions and picking winning stocks, demonstrating their Midas touch in the Indian stock market.
Listed below are such Pharma stocks in which Ace Investors have acquired new stakes during the March quarter:
Jagsonpal Pharmaceuticals Ltd
With a market capitalization of Rs. 955 crores, the shares of Jagsonpal Pharmaceuticals started Saturday’s live special trading session on a higher note at Rs. 361 compared to its previous close of Rs. 357.70. During the trading session, the shares hit a high of Rs. 375.50, gaining around 2 percent and closed the trading session at Rs. 361.05 apiece.
Looking at the company’s financial statements, the revenue decreased by 18 percent from Rs. 57.83 crores during the September quarter to Rs. 47.25 crores in the December quarter. On the other hand, the net profits declined by 47 percent from Rs. 7.47 crores to Rs. 3.96 crores during the same period.
According to the BSE data, Ace Investor Mr Mukul Agrawal entered the stock in March 2024, by acquiring approximately 4.63 lakh equity shares equivalent to a 1.75 percent stake in this company. The current holding value of his investment amounts to Rs. 16.7 crores.
The Ace investor had previously entered into the company’s shares in June 2022 but divested entirely from the position by September 2023.
Due to increasing operating revenue and profits on a YoY basis, the profitability metrics of the company improved with the return on equity (RoE) increasing from 15.28 percent during FY 21-22 to 18.32 percent in FY 22-23, and, the return on capital employed (RoCE) zoomed from 21.14 percent to 23.48 percent during the same timeframe. Furthermore, the net profit margin increased from 8.67 percent during FY21-22 to 11.29 percent during FY22-23.
Sanjivani Paranteral Ltd
With a market capitalization of Rs. 218 crores, the shares of Sanjivani Paranteral started Saturday’s live special trading session on a higher note at Rs. 185.50 compared to its previous close of Rs. 184.15. During the trading session, the shares hit a high of Rs. 191.75, gaining around 2 percent and closed the day at Rs. 186 apiece.
Coming onto the company’s financial statements, the revenue decreased by 14 percent from Rs. 14.96 crores during the December quarter to Rs. 12.86 crores in the March quarter. In addition, the net profits declined by 24 percent from Rs. 1.65 crores to Rs. 1.26 crores during the same period.
According to the BSE data, Ace Investor Mr Ashish Kacholia entered the stock in March 2024, by acquiring approximately 3.70 lakh equity shares equivalent to a 3.17 percent stake in this company. The current holding value of his investment amounts to Rs. 6.9 crores.
Looking at the company’s important financial ratios, the Return on Equity (ROE) declined from 12.85 percent in FY21-22 to 8.35 percent in FY22-23. Conversely, the Return on Capital Employed (RoCE) improved from 7.94 percent to 9.05 percent over the same period. Additionally, the Net Profit Margin decreased from 15.84 percent in FY21-22 to 10.88 percent in FY22-23.
Written By Vaibhav Patil
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
